IL141410A0 - Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) - Google Patents
Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)Info
- Publication number
- IL141410A0 IL141410A0 IL14141099A IL14141099A IL141410A0 IL 141410 A0 IL141410 A0 IL 141410A0 IL 14141099 A IL14141099 A IL 14141099A IL 14141099 A IL14141099 A IL 14141099A IL 141410 A0 IL141410 A0 IL 141410A0
- Authority
- IL
- Israel
- Prior art keywords
- arylpiperazines
- mmp
- inhibiting agents
- metalloproteinase inhibiting
- metalloproteinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98402144 | 1998-08-31 | ||
EP99401351 | 1999-06-04 | ||
PCT/GB1999/002801 WO2000012478A1 (en) | 1998-08-31 | 1999-08-25 | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
Publications (1)
Publication Number | Publication Date |
---|---|
IL141410A0 true IL141410A0 (en) | 2002-03-10 |
Family
ID=26151689
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14141099A IL141410A0 (en) | 1998-08-31 | 1999-08-25 | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
IL141410A IL141410A (en) | 1998-08-31 | 2001-02-13 | Arylpiprazines, the process for their preparation, the pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of disease states mediated by metalloproteinases (MMP) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL141410A IL141410A (en) | 1998-08-31 | 2001-02-13 | Arylpiprazines, the process for their preparation, the pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of disease states mediated by metalloproteinases (MMP) |
Country Status (33)
Country | Link |
---|---|
US (2) | US6734184B1 (xx) |
EP (1) | EP1109787B1 (xx) |
JP (1) | JP4776778B2 (xx) |
KR (1) | KR100771454B1 (xx) |
CN (1) | CN1183119C (xx) |
AT (1) | ATE326448T1 (xx) |
AU (1) | AU764367B2 (xx) |
BG (1) | BG65426B1 (xx) |
BR (1) | BR9913255A (xx) |
CA (1) | CA2339761C (xx) |
CY (1) | CY1106139T1 (xx) |
DE (1) | DE69931375T2 (xx) |
DK (1) | DK1109787T3 (xx) |
EE (1) | EE05005B1 (xx) |
ES (1) | ES2263284T3 (xx) |
GB (1) | GB9919776D0 (xx) |
HK (1) | HK1036060A1 (xx) |
HU (1) | HUP0103344A3 (xx) |
ID (1) | ID28786A (xx) |
IL (2) | IL141410A0 (xx) |
IS (1) | IS5849A (xx) |
MX (1) | MXPA01001847A (xx) |
MY (1) | MY129409A (xx) |
NO (1) | NO321478B1 (xx) |
NZ (2) | NZ524921A (xx) |
PL (1) | PL199894B1 (xx) |
PT (1) | PT1109787E (xx) |
RU (1) | RU2220967C2 (xx) |
SI (1) | SI1109787T1 (xx) |
SK (1) | SK286658B6 (xx) |
TR (1) | TR200100605T2 (xx) |
TW (1) | TWI240722B (xx) |
WO (1) | WO2000012478A1 (xx) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6916817B1 (en) * | 1999-06-04 | 2005-07-12 | Astrazeneca Ab | Inhibitors of metalloproteinases |
WO2001062750A1 (en) * | 2000-02-21 | 2001-08-30 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
WO2001062751A1 (en) * | 2000-02-21 | 2001-08-30 | Astrazeneca Ab | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
RU2283306C2 (ru) * | 2000-02-21 | 2006-09-10 | Астразенека Аб | Пиперидин- и пиперазинзамещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ |
EP1286994A1 (en) | 2000-05-15 | 2003-03-05 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
US6506773B2 (en) | 2000-05-15 | 2003-01-14 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives |
CN1440400A (zh) * | 2000-05-25 | 2003-09-03 | 史密斯克莱·比奇曼公司 | 二环基或杂二环基甲磺酰氨基-取代的n-羟基甲酰胺化合物 |
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
BR0210733A (pt) | 2001-07-02 | 2004-07-20 | Astrazeneca Ab | Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina |
GB0119474D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
ATE420068T1 (de) | 2001-09-07 | 2009-01-15 | Kaken Pharma Co Ltd | Reverse hydroxamsäurederivate |
GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
WO2003040103A1 (en) * | 2001-11-02 | 2003-05-15 | Bristol-Myers Squibb Company | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
ATE399012T1 (de) * | 2002-04-03 | 2008-07-15 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren |
GB0216379D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
GB0216383D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
GB0216382D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221250D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US7465719B2 (en) | 2003-01-17 | 2008-12-16 | Topotarget Uk Limited | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors |
SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
ATE411303T1 (de) * | 2003-06-19 | 2008-10-15 | Ucb Pharma Sa | Hydroxamatsulfonamide als inhibitoren von cd23- shedding |
SE0301922D0 (sv) * | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
GB0427403D0 (en) * | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
AU2005318163B2 (en) * | 2004-12-21 | 2011-12-01 | Merck Serono Sa | Sulfonyl amino cyclic derivatives and use thereof |
FR2885615B1 (fr) * | 2005-05-12 | 2007-06-22 | Servier Lab | Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2885616B1 (fr) * | 2005-05-12 | 2007-06-22 | Servier Lab | Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2615650A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
EA013907B1 (ru) * | 2005-10-26 | 2010-08-30 | Мерк Сероно С.А. | Сульфонамидные производные и их применение для модулирования металлопротеаз |
JP5199109B2 (ja) * | 2005-11-24 | 2013-05-15 | メルク セローノ ソシエテ アノニム | N−ヒドロキシアミド誘導体およびその使用 |
HUE031972T2 (en) | 2005-12-29 | 2017-08-28 | Celtaxsys Inc | Diamin derivatives as leukotriene A4 hydrolase inhibitors |
HUE030114T2 (en) | 2010-07-08 | 2017-04-28 | Kaken Pharma Co Ltd | N-hydroxyformamide derivatives and pharmaceutical compositions containing them |
WO2014121884A1 (en) | 2013-02-06 | 2014-08-14 | Merck Patent Gmbh | Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis |
ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
MX2015011676A (es) | 2013-03-14 | 2016-04-25 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
WO2014152229A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
RU2678196C2 (ru) | 2013-03-14 | 2019-01-24 | Селтакссис, Инк. | Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы |
CA3102077A1 (en) | 2018-05-31 | 2019-12-05 | Sanjeev AHUJA | Method of reducing pulmonary exacerbations in respiratory disease patients |
ES2940695T3 (es) | 2018-06-07 | 2023-05-10 | Idorsia Pharmaceuticals Ltd | Derivados de piridinilo alcoxi-sustituido como antagonistas del receptor LPA1 y su uso en el tratamiento de la fibrosis |
CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3532340A (en) * | 1967-08-11 | 1970-10-06 | Vincent Nardiello | Spring type abdominal exercising device |
ES426195A1 (es) * | 1973-05-18 | 1976-07-01 | Mega Produc U Verpackungsentwi | Perfeccionamientos en aparatos para entrenamiento muscular. |
US4480831A (en) * | 1982-03-12 | 1984-11-06 | Mueller Deinhardt Friedhelm | Exercise hoop having a counter |
BE897714A (nl) * | 1983-09-09 | 1984-01-02 | Nelissen Koenraad | Ring met elastiek en handvat |
US4607625A (en) * | 1985-01-10 | 1986-08-26 | Schenck Robert R | Dynamic traction device |
US4724827A (en) * | 1985-01-10 | 1988-02-16 | Schenck Robert R | Dynamic traction device |
GB9411598D0 (en) * | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
US5674162A (en) * | 1995-06-07 | 1997-10-07 | Ellingson; Richard L. | Biomechanical stabilizer apparatus and methods for strengthening unstable joints and improving muscle coordination |
PL193829B1 (pl) * | 1996-08-07 | 2007-03-30 | Darwin Discovery Ltd | Pochodne kwasów hydroksamowych, środek farmaceutyczny i zastosowanie pochodnych kwasów hydroksamowych w medycynie |
AU743901B2 (en) * | 1996-10-16 | 2002-02-07 | Wyeth Holdings Corporation | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors |
US6333324B1 (en) * | 1996-12-17 | 2001-12-25 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of MMP or TNF |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
JP3563411B2 (ja) | 1997-01-23 | 2004-09-08 | エフ・ホフマン−ラ ロシュ アーゲー | スルファミド−メタロプロテアーゼ阻害剤 |
ZA98376B (en) | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US6482827B1 (en) | 1997-07-10 | 2002-11-19 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
AU8858398A (en) * | 1997-07-10 | 1999-02-08 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
EP1001975A1 (en) * | 1997-07-31 | 2000-05-24 | Elan Pharmaceuticals, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6130220A (en) | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
CA2317455C (en) * | 1998-01-30 | 2011-01-25 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
JP2002518368A (ja) * | 1998-06-17 | 2002-06-25 | デュポン ファーマシューティカルズ カンパニー | メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類 |
EP1107953A1 (en) | 1998-08-29 | 2001-06-20 | British Biotech Pharmaceuticals Limited | Hydroxamic acid derivatives as proteinase inhibitors |
-
1999
- 1999-08-23 GB GBGB9919776.6A patent/GB9919776D0/en not_active Ceased
- 1999-08-25 NZ NZ524921A patent/NZ524921A/en not_active IP Right Cessation
- 1999-08-25 HU HU0103344A patent/HUP0103344A3/hu unknown
- 1999-08-25 KR KR1020017002457A patent/KR100771454B1/ko not_active IP Right Cessation
- 1999-08-25 BR BR9913255-9A patent/BR9913255A/pt not_active IP Right Cessation
- 1999-08-25 CA CA2339761A patent/CA2339761C/en not_active Expired - Fee Related
- 1999-08-25 JP JP2000567511A patent/JP4776778B2/ja not_active Expired - Fee Related
- 1999-08-25 EP EP99941751A patent/EP1109787B1/en not_active Expired - Lifetime
- 1999-08-25 DK DK99941751T patent/DK1109787T3/da active
- 1999-08-25 PT PT99941751T patent/PT1109787E/pt unknown
- 1999-08-25 US US09/763,709 patent/US6734184B1/en not_active Expired - Fee Related
- 1999-08-25 IL IL14141099A patent/IL141410A0/xx active IP Right Grant
- 1999-08-25 CN CNB998125512A patent/CN1183119C/zh not_active Expired - Fee Related
- 1999-08-25 RU RU2001108591/04A patent/RU2220967C2/ru not_active IP Right Cessation
- 1999-08-25 SK SK270-2001A patent/SK286658B6/sk not_active IP Right Cessation
- 1999-08-25 TR TR2001/00605T patent/TR200100605T2/xx unknown
- 1999-08-25 DE DE69931375T patent/DE69931375T2/de not_active Expired - Lifetime
- 1999-08-25 PL PL346344A patent/PL199894B1/pl not_active IP Right Cessation
- 1999-08-25 MX MXPA01001847A patent/MXPA01001847A/es not_active Application Discontinuation
- 1999-08-25 AU AU55247/99A patent/AU764367B2/en not_active Ceased
- 1999-08-25 SI SI9930908T patent/SI1109787T1/sl unknown
- 1999-08-25 ES ES99941751T patent/ES2263284T3/es not_active Expired - Lifetime
- 1999-08-25 EE EEP200100106A patent/EE05005B1/xx not_active IP Right Cessation
- 1999-08-25 ID IDW20010482A patent/ID28786A/id unknown
- 1999-08-25 WO PCT/GB1999/002801 patent/WO2000012478A1/en not_active Application Discontinuation
- 1999-08-25 AT AT99941751T patent/ATE326448T1/de not_active IP Right Cessation
- 1999-08-25 NZ NZ509730A patent/NZ509730A/en not_active IP Right Cessation
- 1999-08-30 TW TW088114833A patent/TWI240722B/zh not_active IP Right Cessation
- 1999-08-30 MY MYPI99003751A patent/MY129409A/en unknown
-
2001
- 2001-02-13 IL IL141410A patent/IL141410A/en not_active IP Right Cessation
- 2001-02-16 IS IS5849A patent/IS5849A/is unknown
- 2001-02-28 NO NO20011023A patent/NO321478B1/no not_active IP Right Cessation
- 2001-03-22 BG BG105369A patent/BG65426B1/bg unknown
- 2001-09-24 HK HK01106732A patent/HK1036060A1/xx not_active IP Right Cessation
-
2004
- 2004-02-26 US US10/787,775 patent/US7342020B2/en not_active Expired - Fee Related
-
2006
- 2006-08-07 CY CY20061101106T patent/CY1106139T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL346344A1 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) | |
GB9801690D0 (en) | Therapeutic agents | |
TR199901191T2 (xx) | Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�. | |
TR199903287T2 (xx) | Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri. | |
TR200003071T2 (tr) | Sistein-proteazı önleyici etkiye sahip yeni heterosiklik ikame edilmiş amidler | |
GB9715030D0 (en) | Metalloproteinase inhibitors | |
PT920426E (pt) | Novos derivados de tiazole com efeito inibidor de fosfodiesterase | |
SI1181294T1 (en) | Novel derivatives and analogues of galanthamin | |
IS5966A (is) | Nýjar amídínóafleiður og notkun þeirra sem þrombínhemlar | |
MY128164A (en) | Compounds | |
NO20015892L (no) | Inhibitorer av metallproteinaser | |
BG104575A (en) | Matrix metalloprotease inhibitors | |
SI1377574T1 (xx) | ||
NO20023951L (no) | Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler | |
MXPA02011558A (es) | Inhibidores de mmp-2/mp-9 novedosos. | |
GB2324091A (en) | Metalloproteinase inhibitors | |
TR200100133T2 (tr) | FKBP İnhibitörleri | |
YU79602A (xx) | Tip 1 (nhe-1) inhibitor natrijum-vodonik izmenjiva^a | |
AU2001232113A1 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) | |
BR0007278A (pt) | Inibidores de hidroxamato reverso demetalo-proteinases de matriz | |
BG105252A (en) | Isoquinolines as urokinase inhibitors | |
AP2001002047A0 (en) | Isoquinoliness as urokinase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |